PL2024368T3 - Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu - Google Patents

Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu

Info

Publication number: PL2024368T3
Authority: PL; Poland
Prior art keywords: trpv1; azepin; pyrimido; tetrahydro; modulators
Prior art date: 2006-03-21

Application number

PL07753768T

Other languages

English (en)

Inventor

Brett D Allison

Bryan James Branstetter

James Guy Breitenbucher

Michael D Hack

Natalie A Hawryluk

Alec D Lebsack

Kelly J Mcclure

Jeffrey E Merit

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-21

Filing date

2007-03-21

Publication date

2014-09-30

2007-03-21 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2014-09-30 Publication of PL2024368T3 publication Critical patent/PL2024368T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)

PL07753768T 2006-03-21 2007-03-21 Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu PL2024368T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US78541506P	2006-03-21	2006-03-21
PCT/US2007/007166 WO2007109355A2 (en)	2006-03-21	2007-03-21	6,7,8, 9 -tetrahydro- 5h- pyrimido [4, 5-d] azepin-4-yl] -amine derivatives as modulators of trpvl for the treatment of pain
EP07753768.6A EP2024368B1 (en)	2006-03-21	2007-03-21	6,7,8,9-tetrahydro-5h-pyrimido[4,5-d]azepin-4-yl]-amine derivatives as modulators of trpv1 for the treatment of pain

Publications (1)

Publication Number	Publication Date
PL2024368T3 true PL2024368T3 (pl)	2014-09-30

Family

ID=38353855

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07753768T PL2024368T3 (pl)	2006-03-21	2007-03-21	Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu

Country Status (30)

Country	Link
US (3)	US8673895B2 (pl)
EP (1)	EP2024368B1 (pl)
JP (1)	JP5232768B2 (pl)
KR (1)	KR101461376B1 (pl)
CN (1)	CN101448835B (pl)
AR (1)	AR059985A1 (pl)
AU (1)	AU2007227203B2 (pl)
BR (1)	BRPI0709034B1 (pl)
CA (1)	CA2646977C (pl)
CR (1)	CR10387A (pl)
DK (1)	DK2024368T3 (pl)
EA (1)	EA017069B1 (pl)
EC (1)	ECSP088807A (pl)
ES (1)	ES2474152T3 (pl)
HR (1)	HRP20140664T1 (pl)
MX (1)	MX2008012163A (pl)
NI (1)	NI200800253A (pl)
NO (1)	NO341676B1 (pl)
NZ (1)	NZ571343A (pl)
PE (1)	PE20080145A1 (pl)
PL (1)	PL2024368T3 (pl)
PT (1)	PT2024368E (pl)
RS (1)	RS53436B (pl)
SG (1)	SG177176A1 (pl)
SI (1)	SI2024368T1 (pl)
TW (1)	TWI440639B (pl)
UA (1)	UA92636C2 (pl)
UY (1)	UY30229A1 (pl)
WO (1)	WO2007109355A2 (pl)
ZA (1)	ZA200808975B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69638073D1 (de) *	1996-09-04	2009-12-24	Intertrust Tech Corp	Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung
WO2008057300A2 (en) *	2006-10-27	2008-05-15	Redpoint Bio Corporation	Trpvi antagonists and uses thereof
JP2010522156A (ja) *	2007-03-23	2010-07-01	ファイザー・リミテッド	５−ＨＴ２ｃ作動薬としてのピリミド［４，５−ｄ］アゼピン誘導体
WO2009078999A1 (en)	2007-12-17	2009-06-25	Janssen Pharmaceutica N.V.	Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009079000A1 (en) *	2007-12-17	2009-06-25	Janssen Pharmaceutica N.V.	Imidazolopyrimidine modulators of trpv1
MX2011001196A (es) *	2008-07-31	2011-05-30	Genentech Inc	Compuestos de pirimidina, composiciones y metodos de uso.
KR20110082189A (ko) *	2008-11-06	2011-07-18	아스트라제네카 아베	아밀로이드 베타의 조절제
CA2766151A1 (en) *	2009-06-24	2010-12-29	Genentech, Inc.	Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
RU2515541C2 (ru) *	2009-11-12	2014-05-10	Ф.Хоффманн-Ля Рош Аг	N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения
US8288381B2 (en) *	2009-11-12	2012-10-16	Genentech, Inc.	N-9 substituted purine compounds, compositions and methods of use
DK2585216T3 (da) *	2010-06-23	2020-02-03	Johnson Matthey Plc	Pi-allylpalladium- og pi-allylnickel-komplekser til anvendelse som katalysatorer i carbon-carbon- og carbon-nitrogen-koblingsreaktioner
CN102154494B (zh) *	2011-03-14	2013-01-02	中国人民解放军军事医学科学院基础医学研究所	一种用于儿童哮喘检测的标志物
ES2698359T3 (es)	2013-02-20	2019-02-04	Lg Chemical Ltd	Agonistas del receptor de la esfingosina-1-fosfato, métodos para preparar los mismos y composiciones farmacéuticas que los contienen como agentes activos
CN103641762A (zh) *	2013-12-18	2014-03-19	中国药科大学	一类trpv1/cox-2双重抑制剂、其制备方法及其制备镇痛药物的用途
CN113727758A (zh) *	2019-03-01	2021-11-30	锐新医药公司	双环杂环基化合物及其用途
NZ789014A (en)	2019-12-03	2025-07-25	Lg Chemical Ltd	Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4160834A (en) *	1977-03-09	1979-07-10	Eli Lilly And Company	1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
JPH03167178A (ja)	1989-11-24	1991-07-19	Taiji Nakayama	ピリミジン誘導体
JPH03255077A (ja)	1990-03-01	1991-11-13	Taiji Nakayama	ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
WO1993014080A1 (en)	1992-01-15	1993-07-22	E.I. Du Pont De Nemours And Company	Bridged heterocyclic fungicides
JPH06172355A (ja)	1992-04-14	1994-06-21	Mect Corp	ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
JPH0625243A (ja)	1992-07-08	1994-02-01	Sankyo Co Ltd	１−メチルカルバペネム誘導体の製造法
DE19624069A1 (de)	1996-06-17	1997-12-18	Thomae Gmbh Dr K	Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4332168A1 (de)	1993-02-22	1995-03-23	Thomae Gmbh Dr K	Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6150343A (en) *	1993-06-30	2000-11-21	University Of Pittsburgh	Camptothecin analogs and methods of preparation thereof
US5512563A (en) *	1993-07-29	1996-04-30	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
US5834461A (en) *	1993-07-29	1998-11-10	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
US5428040A (en)	1993-08-31	1995-06-27	The Du Pont Merck Pharmaceutical Company	Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
AR002459A1 (es)	1995-01-17	1998-03-25	American Cyanamid Co	Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
US5985799A (en)	1995-11-17	1999-11-16	E.I. Du Pont De Nemours And Company	Tricyclic herbicidal heterocycles
US6107300A (en) *	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
JP3531169B2 (ja)	1996-06-11	2004-05-24	三菱ウェルファーマ株式会社	縮合ヘテロ環化合物およびその医薬用途
WO1997047624A1 (en)	1996-06-13	1997-12-18	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
EP0973778A1 (en)	1997-03-07	2000-01-26	Novo Nordisk A/S	4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
ZA982368B (en) *	1997-03-27	1998-09-23	Akzo Nobel Nv	New therapeutic combinations
USRE38524E1 (en)	1997-06-25	2004-06-01	Pfizer Inc.	Dipeptide derivatives as growth hormone secretagogues
US6232320B1 (en) *	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
US6358951B1 (en) *	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP2001097979A (ja)	1999-07-28	2001-04-10	Takeda Chem Ind Ltd	縮合複素環化合物、その製造法および用途
US7160890B2 (en) *	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
JP2001294572A (ja)	2000-02-09	2001-10-23	Dai Ichi Seiyaku Co Ltd	新規スルホニル誘導体
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DOP2001000154A (es) *	2000-05-25	2002-05-15	Pfizer Prod Inc	Combinación de secretagogos de hormona del crecimiento y antidepresivos
ATE446758T1 (de) *	2000-05-31	2009-11-15	Pfizer Prod Inc	Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL143690A0 (en) *	2000-06-19	2002-04-21	Pfizer Prod Inc	The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
BR0111567A (pt) *	2000-06-28	2003-05-06	Pfizer Prod Inc	Ligandos do receptor de melanocortina
IL143942A0 (en) *	2000-06-29	2002-04-21	Pfizer Prod Inc	Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) *	2000-06-29	2002-04-10	Pfizer Products Inc.	Use of growth hormone secretagogues for stimulating or increasing appetite
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
ATE302751T1 (de) *	2000-06-30	2005-09-15	Elan Pharm Inc	Verbindungen zur behandlung der alzheimerischen krankheit
US6369222B1 (en)	2000-07-18	2002-04-09	Hoffmann-La Roche Inc.	mGluR antagonists and a method for their synthesis
AUPQ887100A0 (en) *	2000-07-19	2000-08-10	Dynamic Digital Depth Research Pty Ltd	Image processing and encoding techniques
IL144468A0 (en) *	2000-07-27	2002-05-23	Pfizer Prod Inc	Use of growth hormone secretagogues for improvement of functional health status
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
KR20030032035A (ko)	2000-09-15	2003-04-23	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피라졸 화합물
IL145540A0 (en) *	2000-09-28	2002-06-30	Pfizer Prod Inc	Use of growth hormone secretagogues in conjunction with physical exercise
WO2002032872A1 (fr) *	2000-10-20	2002-04-25	Eisai Co., Ltd.	Composes a noyau aromatique azote
MXPA03005610A (es) *	2000-12-21	2003-10-06	Vertex Pharma	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
CA2668823A1 (en) *	2000-12-27	2002-07-04	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Process for the preparation of .alpha.-aminosubstituted carboxylic acid amides
WO2002088079A2 (en) *	2001-05-01	2002-11-07	Bristol-Myers Squibb Company	Dual inhibitors of pde 7 and pde 4
US7105667B2 (en) *	2001-05-01	2006-09-12	Bristol-Myers Squibb Co.	Fused heterocyclic compounds and use thereof
US6686352B2 (en) *	2001-05-18	2004-02-03	Hoffmann-La Roche Inc.	Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
CA2464031A1 (en) *	2001-10-30	2003-05-08	Conforma Therapeutics Corporation	Purine analogs having hsp90-inhibiting activity
HUP0402018A3 (en) *	2001-11-30	2008-06-30	Schering Corp	5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
WO2003062209A2 (en)	2002-01-17	2003-07-31	Neurogen Corporation	Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
JP2003321472A (ja)	2002-02-26	2003-11-11	Takeda Chem Ind Ltd	Ｇｒｋ阻害剤
US20030199514A1 (en)	2002-03-27	2003-10-23	Fryburg David A.	Methods for improving efficacy of treatment with growth hormone secretagogues
AU2003242252A1 (en) *	2002-06-07	2003-12-22	Kyowa Hakko Kogyo Co., Ltd.	Bicyclic pyrimidine derivatives
US20030139427A1 (en) *	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
GB0221828D0 (en)	2002-09-20	2002-10-30	Astrazeneca Ab	Novel compound
AU2003291310A1 (en) *	2002-11-06	2004-06-03	Bristol-Myers Squibb Company	Fused heterocyclic compounds and use thereof
US7265138B2 (en) *	2003-02-10	2007-09-04	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
AR045979A1 (es) *	2003-04-28	2005-11-23	Astrazeneca Ab	Amidas heterociclicas
WO2004108120A1 (en)	2003-06-11	2004-12-16	Pfizer Products Inc.	Use of growth hormone secretagogues for treatment of fibromyalgia
WO2005007655A1 (en)	2003-07-21	2005-01-27	Pfizer Products Inc.	Nicotine addiction reducing heteroaryl fused azapolycyclic compounds
CN1894222A (zh) *	2003-08-05	2007-01-10	沃泰克斯药物股份有限公司	作为电压门控离子通道抑制剂的稠合嘧啶化合物
WO2005014548A1 (ja)	2003-08-08	2005-02-17	Sumitomo Chemical Company, Limited	ジソピラミド遊離塩基の低融点型結晶の製造方法
JP2007520444A (ja)	2003-09-09	2007-07-26	ニューロジェン・コーポレーション	置換二環式キナゾリン−４−イルアミン誘導体
EP1670794A2 (en)	2003-09-30	2006-06-21	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
EP1675862A1 (en) *	2003-10-07	2006-07-05	AstraZeneca AB	New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20070135454A1 (en)	2003-11-14	2007-06-14	Tracy Bayliss	Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
US7816356B2 (en) *	2003-11-14	2010-10-19	Daniel Yohannes	Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
JP2005162673A (ja)	2003-12-03	2005-06-23	Kyowa Hakko Kogyo Co Ltd	二環性ピリミジン誘導体
US7312330B2 (en) *	2003-12-24	2007-12-25	Renovis, Inc.	Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en)	2003-12-24	2005-09-16	Renovis Inc	Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2005070929A1 (en)	2004-01-23	2005-08-04	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
WO2005082865A1 (ja) *	2004-02-27	2005-09-09	Astellas Pharma Inc.	縮合二環性ピリミジン誘導体
WO2005095419A1 (ja)	2004-04-01	2005-10-13	Takeda Pharmaceutial Company Limited	チアゾロピリミジン誘導体
GB0412467D0 (en)	2004-06-04	2004-07-07	Astrazeneca Ab	Chemical compounds
ITMI20041231A1 (it)	2004-06-18	2004-09-18	Pharmeste Srl	Antagonisti del recettore dei vanilloidi trpv1
US7617501B2 (en)	2004-07-09	2009-11-10	Quest Software, Inc.	Apparatus, system, and method for managing policies on a computer having a foreign operating system
ITMI20041566A1 (it)	2004-07-30	2004-10-30	Indena Spa	"trpv1 agonisti, formulazioni che li contengono e loro usi"
FR2874015B1 (fr) *	2004-08-05	2006-09-15	Sanofi Synthelabo	Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP2006083085A (ja)	2004-09-15	2006-03-30	Kyowa Hakko Kogyo Co Ltd	二環性ピリミジン誘導体の製造法およびその合成中間体
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
WO2006041773A2 (en) *	2004-10-04	2006-04-20	Millennium Pharmaceuticals, Inc.	Lactam compounds useful as protein kinase inhibitors
WO2006044762A2 (en) *	2004-10-15	2006-04-27	Bayer Pharmaceuticals Corporation	Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
WO2006065484A2 (en)	2004-11-24	2006-06-22	Abbott Laboratories	Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
US20060128710A1 (en)	2004-12-09	2006-06-15	Chih-Hung Lee	Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
CN101232885A (zh)	2005-01-25	2008-07-30	神经能质公司	经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物
CA2608718A1 (en)	2005-05-18	2006-11-23	Pfizer Limited	1, 2, 4-triazole derivatives as vasopressin antagonists
PE20070171A1 (es)	2005-06-30	2007-03-08	Boehringer Ingelheim Int	GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US20070032473A1 (en) *	2005-07-19	2007-02-08	Kai Gerlach	Substituted amides and their use as medicaments
KR101353268B1 (ko) *	2005-08-04	2014-02-06	얀센 파마슈티카 엔.브이.	세로토닌 수용체 모듈레이터로서의 피리미딘 화합물
US7598255B2 (en) *	2005-08-04	2009-10-06	Janssen Pharmaceutica Nv	Pyrimidine compounds as serotonin receptor modulators
US20070136603A1 (en) *	2005-10-21	2007-06-14	Sensis Corporation	Method and apparatus for providing secure access control for protected information
TW200738649A (en)	2005-11-22	2007-10-16	Smithkline Beecham Corp	Calcilytic compounds
JP4678685B2 (ja)	2005-12-26	2011-04-27	株式会社吉野工業所	エアゾール式液噴出器
DE102005062987A1 (de)	2005-12-28	2007-07-05	Grünenthal GmbH	Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
EP1991528A2 (en)	2006-01-18	2008-11-19	Siena Biotech S.p.A.	Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
EP1818330A1 (de)	2006-02-14	2007-08-15	Boehringer Ingelheim Pharma GmbH & Co.KG	Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
AU2007225273A1 (en) *	2006-03-10	2007-09-20	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
BRPI0709035A2 (pt)	2006-03-21	2011-06-21	Schering Corp	compostos de piridina substituìda heterocìclica com atividade antagonista de cxcr3
CA2652367A1 (en)	2006-05-16	2007-11-29	Merck & Co., Inc.	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20080051387A1 (en)	2006-06-09	2008-02-28	Yuelian Xu	Tetrahydropyrido[3,4-d]pyrimidines and related analogues
JP2009007273A (ja)	2007-06-27	2009-01-15	Ajinomoto Co Inc	ジアミノピリミジン化合物の製造方法

2007
- 2007-03-19 PE PE2007000298A patent/PE20080145A1/es not_active Application Discontinuation
- 2007-03-20 AR ARP070101128A patent/AR059985A1/es active IP Right Grant
- 2007-03-20 TW TW096109423A patent/TWI440639B/zh not_active IP Right Cessation
- 2007-03-21 BR BRPI0709034-0A patent/BRPI0709034B1/pt not_active IP Right Cessation
- 2007-03-21 AU AU2007227203A patent/AU2007227203B2/en not_active Ceased
- 2007-03-21 RS RS20140377A patent/RS53436B/sr unknown
- 2007-03-21 PT PT77537686T patent/PT2024368E/pt unknown
- 2007-03-21 JP JP2009501567A patent/JP5232768B2/ja active Active
- 2007-03-21 KR KR1020087025462A patent/KR101461376B1/ko not_active Expired - Fee Related
- 2007-03-21 WO PCT/US2007/007166 patent/WO2007109355A2/en not_active Ceased
- 2007-03-21 EA EA200802020A patent/EA017069B1/ru unknown
- 2007-03-21 SG SG2011089356A patent/SG177176A1/en unknown
- 2007-03-21 SI SI200731477T patent/SI2024368T1/sl unknown
- 2007-03-21 PL PL07753768T patent/PL2024368T3/pl unknown
- 2007-03-21 DK DK07753768.6T patent/DK2024368T3/da active
- 2007-03-21 MX MX2008012163A patent/MX2008012163A/es active IP Right Grant
- 2007-03-21 CN CN2007800182597A patent/CN101448835B/zh active Active
- 2007-03-21 UY UY30229A patent/UY30229A1/es not_active Application Discontinuation
- 2007-03-21 UA UAA200812338A patent/UA92636C2/ru unknown
- 2007-03-21 HR HRP20140664TT patent/HRP20140664T1/hr unknown
- 2007-03-21 NZ NZ571343A patent/NZ571343A/en not_active IP Right Cessation
- 2007-03-21 ES ES07753768.6T patent/ES2474152T3/es active Active
- 2007-03-21 EP EP07753768.6A patent/EP2024368B1/en active Active
- 2007-03-21 US US11/726,756 patent/US8673895B2/en active Active
- 2007-03-21 CA CA2646977A patent/CA2646977C/en active Active
2008
- 2008-09-19 NI NI200800253A patent/NI200800253A/es unknown
- 2008-10-08 EC EC2008008807A patent/ECSP088807A/es unknown
- 2008-10-20 ZA ZA2008/08975A patent/ZA200808975B/en unknown
- 2008-10-21 NO NO20084411A patent/NO341676B1/no not_active IP Right Cessation
- 2008-10-21 CR CR10387A patent/CR10387A/es not_active Application Discontinuation
2014
- 2014-01-17 US US14/157,671 patent/US9422293B2/en active Active
2016
- 2016-07-12 US US15/207,805 patent/US9738649B2/en active Active

Also Published As

Publication number	Publication date
UY30229A1 (es)	2007-07-31
ECSP088807A (es)	2008-11-27
EP2024368B1 (en)	2014-04-30
US20140135311A1 (en)	2014-05-15
HK1129888A1 (en)	2009-12-11
PE20080145A1 (es)	2008-02-11
US8673895B2 (en)	2014-03-18
NZ571343A (en)	2011-09-30
WO2007109355A3 (en)	2007-11-15
JP2009530396A (ja)	2009-08-27
US9422293B2 (en)	2016-08-23
UA92636C2 (en)	2010-11-25
SI2024368T1 (sl)	2014-08-29
CN101448835B (zh)	2012-06-27
KR20090006098A (ko)	2009-01-14
US20160318942A1 (en)	2016-11-03
NI200800253A (es)	2012-11-30
TW200813061A (en)	2008-03-16
HRP20140664T1 (hr)	2014-10-10
CA2646977A1 (en)	2007-09-27
AU2007227203A1 (en)	2007-09-27
BRPI0709034A2 (pt)	2011-06-21
RS53436B (sr)	2014-12-31
CA2646977C (en)	2015-08-25
KR101461376B1 (ko)	2014-11-26
PT2024368E (pt)	2014-07-17
AU2007227203B2 (en)	2013-01-10
TWI440639B (zh)	2014-06-11
ES2474152T3 (es)	2014-07-08
CR10387A (es)	2009-02-23
SG177176A1 (en)	2012-01-30
CN101448835A (zh)	2009-06-03
JP5232768B2 (ja)	2013-07-10
EA017069B1 (ru)	2012-09-28
ZA200808975B (en)	2009-12-30
BRPI0709034B1 (pt)	2022-05-31
MX2008012163A (es)	2008-12-16
EP2024368A2 (en)	2009-02-18
US20070225275A1 (en)	2007-09-27
WO2007109355A2 (en)	2007-09-27
AR059985A1 (es)	2008-05-14
NO20084411L (no)	2008-11-03
NO341676B1 (no)	2017-12-18
DK2024368T3 (da)	2014-05-19
EA200802020A1 (ru)	2009-04-28
US9738649B2 (en)	2017-08-22

Publication	Publication Date	Title
PL2024368T3 (pl)	2014-09-30	Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu
IL204693A0 (en)	2010-11-30	Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
ZA200708591B (en)	2009-01-28	Pyrimidine derivatives for treatment of hyperproliferative disorders
IL195017A0 (en)	2009-08-03	Pyrazolo [3,4-d]pyrimidine derivatives useful to treat respiratory disorders
IL194076A (en)	2015-05-31	Benzo Compounds - [d] - Imidzo [2, 1 – b] Thiazole-2-Ilphenyl for the Treatment of Illness
WO2009024542A3 (en)	2009-05-22	Purin derivatives for use in the treatment of fab-related diseases
ZA201004368B (en)	2013-01-30	Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
IL195238A0 (en)	2009-08-03	Pyrazolo [1,5-a]pyrimidines as cdk inhibitors
IL191059A0 (en)	2008-12-29	Pyrazine derivatives as sodium channel modulators for the treatment of pain
EP2034834A4 (en)	2010-03-24	PRODRUGS OF 5-AMINO-3- (3'-DEOXY-BETA-D-RIBOFURANOSYL) -THIAZOL [4,5-D] PYRIMIDIN-2,7-DION
IL201209A0 (en)	2010-05-31	Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
TNSN07440A1 (en)	2009-03-17	Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
EP2207555A4 (en)	2010-11-24	NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF
ZA201000581B (en)	2011-04-28	1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL192933A0 (en)	2009-02-11	Benzoisoindole derivatives for the treatment of pain
IL189524A0 (en)	2008-08-07	Imidazole compounds for the treatment of neurological disorders
ZA200705035B (en)	2009-06-24	Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
IL187441A0 (en)	2008-02-09	Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
IL209179A0 (en)	2011-01-31	Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
ZA200809016B (en)	2010-04-28	4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
BRPI0714307A2 (pt)	2014-06-10	Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
ZA201003599B (en)	2012-10-31	Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic anuerysms
GB0725077D0 (en)	2008-01-30	Antifolate com[ounds for the treatment of melanoma
HK1113141A (en)	2008-09-26	Pyrrolo [2,3-d] imidazoles for the treatment of hyperproliferative disorders
ZA200806180B (en)	2009-07-29	Benzoisoindole derivatives for the treatment of pain